tiprankstipranks
Arvinas Announces Updates on Clinical Trials Progress
Company Announcements

Arvinas Announces Updates on Clinical Trials Progress

Story Highlights
  • Arvinas updated guidance for Phase 3 trials of vepdegestrant targeting breast cancer.
  • The company plans new trials and data presentations in 2025, indicating potential value.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Stay Ahead of the Market:

Arvinas Holding Company ( (ARVN) ) has provided an announcement.

Arvinas announced updated guidance for its Phase 3 clinical trials involving vepdegestrant, a PROTAC ER degrader co-developed with Pfizer, targeting ER+/HER2- breast cancer. The company plans to present data from multiple clinical trials and initiate new trials in 2025, marking significant development milestones and potential value for patients and stakeholders.

More about Arvinas Holding Company

Arvinas is a clinical-stage biotechnology company focused on developing protein degradation therapies through its PROTAC platform to treat debilitating and life-threatening diseases. The company is involved in clinical programs targeting estrogen receptor-positive breast cancer, B-cell lymphoma, and neurodegenerative disorders.

YTD Price Performance: 4.92%

Average Trading Volume: 770,544

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $1.36B

For a thorough assessment of ARVN stock, go to TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App

Latest News Feed

More Articles